bimiralisib (PQR309) / PIQUR  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bimiralisib (PQR309) / Torqur
NCT02850744: Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

Terminated
2
10
Europe
PQR309, temozolomide
PIQUR Therapeutics AG, University Hospital, Basel, Switzerland, University Hospital Inselspital, Berne, University Hospital, Zürich
Glioblastoma Multiforme
11/17
11/17
NCT02669511 / 2015-001306-33: PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Completed
2
21
NA
PQR309, bimiralisib
PIQUR Therapeutics AG
Primary Central Nervous System Lymphoma
01/18
01/18
NCT02249429 / 2014-005384-33: Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Completed
2
53
Europe, US, RoW
bimiralisib, PQR309, PI3K Inhibitor (phosphatidylinositol 3-kinase)
PIQUR Therapeutics AG, University College London Hospitals, Churchill Hospital, Royal Marsden NHS Foundation Trust, University of Haifa, Weill Medical College of Cornell University, Institut Curie, University Clinical Center, Sarajevo, Clinical Center Kragujevac, Clinical Center Nis, Nis, Institute for Oncology and Radiology Serbia, Belgrade, University Clinical Centre of Republic of Srpska
Lymphoma, Malignant
09/18
09/18
NCT03120000: PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Withdrawn
2
0
Europe
PQR309
PIQUR Therapeutics AG
Primary Central Nervous System Lymphoma
12/18
12/19
NCT03127020 / 2016-000125-38: Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Completed
2
9
Europe
PQR309, PI3K Inhibitor (phosphatidylinositol 3-kinase)
PIQUR Therapeutics AG, University Hospital, Basel, Switzerland, University Hospital Munich, University Hospital Freiburg, Charite University, Berlin, Germany, University of Stuttgart
Lymphoma, Non-Hodgkin Lymphoma
03/19
 
2019-001189-14: A study to explore the safety and efficacy of bimiralisib applied to the skin in patients with an inflammatory skin condition

Not yet recruiting
2
36
Europe
Topical bimiralisib gel, Daivobet, Daivonex, PQR309, Gel, Ointment, Daivobet, Daivonex
PIQUR Therapeutics AG, PIQUR Therapeutics AG
inflammatory and hyperproliferative skin condition, inflammatory skin condition, Diseases [C] - Immune System Diseases [C20]
 
 
PQR309-009, NCT03740100: Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

Terminated
2
8
US
Bimiralisib, PQR309, PI3K/mTOR inhibitor
M.D. Anderson Cancer Center
HNSCC
08/20
12/20
NCT06319794: Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

Recruiting
2
40
Europe
Bimiralisib
TORQUR
Actinic Keratosis
12/24
12/24
PIQHASSO, NCT02723877 / 2015-004225-14: PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer

Completed
1/2
41
Europe
PQR309, Eribulin, eribulin mesylate, Halaven®
PIQUR Therapeutics AG, Hospital Universitario Ramon y Cajal, Hospital Universitari Vall d'Hebron Research Institute, Institut Català d'Oncologia, Churchill Hospital, Barts Cancer Institute, Fundación Instituto Valenciano de Oncología
Metastatic Breast Cancer
10/18
10/18

Download Options